Author

C. Diorio

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Aug 2026

T-cell immunosenescence limits CD19 CAR T-cell function in chronic lymphocytic leukemia.

CD19-directed CAR T-cells (CTL019) can produce durable remissions in chronic lymphocytic leukemia (CLL), but therapeutic success depends on whether autologous T-cells expand, persist, and retain cytotoxic function after manufacturing. Failure of CLL T-cells is often attributed to exhaustion, although many dysfunctional...

Julia Han Noll, Devin Dersh, Jiang-Yuan Li et al. · Blood · 0 citations

Review Sep 2026

Abstract IA03: Immune Related Toxicities Associated with Immunotherapies

Chimeric antigen receptor T-cell (CART) therapy has revolutionized care for many pediatric cancers, especially relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). Although CART are highly effective, they can induce severe toxicities. The most common severe adverse events associated with CART are cytok...

C. Diorio · Cancer Research · 0 citations

Sep 2026

Multimodal analysis of CD38 in T-cell Acute Lymphoblastic Leukemia Identifies Combinatorial Therapeutic Strategies.

Outcomes for pediatric patients with refractory or relapsed T-cell acute lymphoblastic leukemia (T-ALL) are poor, underscoring the need for improved therapeutic strategies. CD38, a type II transmembrane glycoprotein, is a promising target in T-ALL, with clinical trials evaluating CD38-targeting immunotherapies in front...

R. Shraim, Gong-Ping Shi, Yi-Zhen Li et al. · Blood · 0 citations